Ken Griffin’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-48,100
| Closed | -$907K | – | 10214 |
|
|
2019
Q3 | $907K | Buy |
48,100
+8,300
| +21% | +$94.9K | ﹤0.01% | 5761 |
|
|
2019
Q2 | $468K | Buy |
39,800
+14,100
| +55% | +$171K | ﹤0.01% | 6920 |
|
|
2019
Q1 | $351K | Buy |
25,700
+6,200
| +32% | +$80.3K | ﹤0.01% | 7383 |
|
|
2018
Q4 | $200K | Sell |
19,500
-12,400
| -39% | -$159K | ﹤0.01% | 7864 |
|
|
2018
Q3 | $531K | Buy |
31,900
+15,100
| +90% | +$273K | ﹤0.01% | 6597 |
|
|
2018
Q2 | $265K | Sell |
16,800
-7,200
| -30% | -$109K | ﹤0.01% | 7423 |
|
|
2018
Q1 | $305K | Buy |
24,000
+12,300
| +105% | +$178K | ﹤0.01% | 6725 |
|
|
2017
Q4 | $134K | Sell |
11,700
-4,300
| -27% | -$48K | ﹤0.01% | 7324 |
|
|
2017
Q3 | $196K | Buy |
16,000
+3,500
| +28% | +$36.5K | ﹤0.01% | 6710 |
|
|
2017
Q2 | $143K | Buy |
+12,500
| New | +$231K | ﹤0.01% | 6776 |
|
|
2016
Q2 | – | Sell |
-14,500
| Closed | -$355K | – | 7698 |
|
|
2016
Q1 | $355K | Buy |
14,500
+11,400
| +368% | +$264K | ﹤0.01% | 4878 |
|
|
2015
Q4 | $102K | Buy |
3,100
+1,500
| +94% | +$50.7K | ﹤0.01% | 6657 |
|
|
2015
Q3 | $52K | Sell |
1,600
-2,700
| -63% | -$115K | ﹤0.01% | 7557 |
|
|
2015
Q2 | $228K | Buy |
+4,300
| New | +$156K | ﹤0.01% | 6148 |
|
Ken Griffin's ALDR Position: Q4 2019 in Review
Ken Griffin sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 633,162 shares — an estimated $11.9M sold.
Ken Griffin first reported a position in ALDR in Q3 2014 and held it in 21 quarters. The position peaked at $42.3M in Q1 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Ken Griffin reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Ken Griffin sold 633,162 Alder Biopharmaceuticals shares in Q4 2019, an estimated $11.9M.
- Ken Griffin first reported a position in Alder Biopharmaceuticals in Q3 2014 and held it in 21 quarters.
- Ken Griffin's Alder Biopharmaceuticals position peaked at $42.3M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.